Beam Therapeutics Inc.(BEAM)

Biotechnology · Cambridge, MA

$24.30-0.09 (-0.37%)

Delayed quote: Oct 2, 2026, 3:30 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-02T19:30:40.933Z.

Stored calculation inputs

Calculation as of: 2026-10-02T19:30:40.933Z.

Quote observation: 2026-10-02T19:30:32.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 24.3
Unrounded diluted TTM EPS · period ending 2026-06-30: -0.86

FMP input reference: 6690442df907739cb512a4e89a03dffaa5e4917a6ca2ab3506a10d5d4da185b9

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

BEAM PE Ratio Metrics

PE RATIO

N/A

BEAM Competitors' PE Ratio

BEAM

Beam Therapeutics Inc.

Current

Market Cap

$2.50B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TMDX

TransMedics Group, Inc.

vs BEAM

Market Cap

$2.72B

PE Ratio

20.41

TTM Avg

34.18

3Y Avg

472.96

5Y Avg

472.96

RXRX

Recursion Pharmaceuticals, Inc.

vs BEAM

Market Cap

$2.14B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XRAY

DENTSPLY SIRONA Inc.

vs BEAM

Market Cap

$1.73B

PE Ratio

N/A

TTM Avg

23.72

3Y Avg

50.63

5Y Avg

57.39

NTLA

Intellia Therapeutics, Inc.

vs BEAM

Market Cap

$1.71B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TDOC

Teladoc Health, Inc.

vs BEAM

Market Cap

$998.39M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEO

NeoGenomics, Inc.

vs BEAM

Market Cap

$470.48M

PE Ratio

N/A

TTM Avg

138.05

3Y Avg

184.03

5Y Avg

168.06

NRC

NRC Health

vs BEAM

Market Cap

$459.52M

PE Ratio

80.78

TTM Avg

41.08

3Y Avg

28.16

5Y Avg

28.99

Shoulder Innovations, Inc.

vs BEAM

Market Cap

$397.34M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs BEAM

Market Cap

$41.20M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Beam Therapeutics Inc. (BEAM)	$2.50B	N/A	N/A	N/A	N/A
TransMedics Group, Inc. (TMDX)vs ›	$2.72B	20.41	34.18	472.96	472.96
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.14B	N/A	N/A	N/A	N/A
DENTSPLY SIRONA Inc. (XRAY)vs ›	$1.73B	N/A	23.72	50.63	57.39
Intellia Therapeutics, Inc. (NTLA)vs ›	$1.71B	N/A	N/A	N/A	N/A
Teladoc Health, Inc. (TDOC)vs ›	$998.39M	N/A	N/A	N/A	N/A
NeoGenomics, Inc. (NEO)vs ›	$470.48M	N/A	138.05	184.03	168.06
NRC Health (NRC)vs ›	$459.52M	80.78	41.08	28.16	28.99
Shoulder Innovations, Inc. (SI)vs ›	$397.34M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$41.20M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$24.30

Forward EPS (Est.)

$-4.43

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

About Beam Therapeutics Inc.

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Cambridge, MA

540 employees

www.beamtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: John Evans

View full financials

NAME

MARKET CAP

PE RATIO

TTM

Beam Therapeutics Inc. (BEAM)

$2.50B

N/A

TransMedics Group, Inc. (TMDX)vs ›

$2.72B

20.41

34.18

472.96

Recursion Pharmaceuticals, Inc. (RXRX)vs ›

$2.14B

N/A

DENTSPLY SIRONA Inc. (XRAY)vs ›

$1.73B

N/A

23.72

50.63

57.39

Intellia Therapeutics, Inc. (NTLA)vs ›

$1.71B

N/A

Teladoc Health, Inc. (TDOC)vs ›

$998.39M

N/A

NeoGenomics, Inc. (NEO)vs ›

$470.48M

N/A

138.05

184.03

168.06

NRC Health (NRC)vs ›

$459.52M

80.78

41.08

28.16

28.99

Shoulder Innovations, Inc. (SI)vs ›

$397.34M

N/A

PDS Biotechnology Corporation (PDSB)vs ›

$41.20M

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

BEAM PE Ratio Metrics

BEAM Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics

PE Ratio: N/A

BEAM PE Ratio Metrics

BEAM Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics